Hindustan Foods Limited, is pleased to announce the commencement of operations of Phase 1 of the new ice cream manufacturing ...

While others played safe, Shanghvi bet on complex generics and specialty pharma, and rode a wave of acquisitions to make Sun ...

Indian benchmark Nifty 50 spent the day in the green. Nifty opened at 24,070 and ended the day at 24,329 gaining 289 points.

After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical ...

The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck ...

The US Court of Appeals for the Federal Circuit has paved the way for the launch of Leqselvi in the US, after almost a year of legal battle over the patent. According to market estimates, Leqselvi is ...

The US Court of Appeals has vacated a preliminary injunction that had stalled Sun Pharma’s launch of Leqselvi in the U.S., a move analysts see as a key positive for the company. Emkay Global Financial ...

The injunction had temporarily barred Sun Pharma from launching Leqselvi in the United States due to an ongoing legal battle with Incyte Corporation. The appellate court's decision, which came shortly ...

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...

Sun Pharma shares gained after a U.S. court lifted an injunction, clearing the way for the launch of LEQSELVI, its drug for autoimmune-related hair loss. The legal battle with Incyte continues, but ...